Addressing lipid treatment targets beyond cholesterol: A role for prescription omega-3 fatty acid therapy

Southern Medical Journal

Volumn 102, Issue 4, 2009, Pages 390-396

  Dall, Tara L ^a   Bays, Harold ^b  

^a Advanced Lipidology   (United States)

^b NONE

Author keywords

Non high density lipoprotein cholesterol; Omega 3 fatty acid; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CERIVASTATIN; CLOFIBRATE; COLESTIPOL; ESTROGEN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; IMMUNOSUPPRESSIVE AGENT; ISOTRETINOIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PROTEINASE INHIBITOR; SIMVASTATIN; TAMOXIFEN; THIAZIDE DIURETIC AGENT; VITAMIN;

ABDOMINAL PAIN; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY ATHEROSCLEROSIS; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DYSLIPIDEMIA; DYSPEPSIA; ECZEMA; EPIGASTRIC DISCOMFORT; EPISTAXIS; FISHY AFTERTASTE; FLUSHING; GASTRITIS; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMOBILIZATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MONOTHERAPY; MYALGIA; MYOPATHY; NAUSEA; OBESITY; PANCREATITIS; PRESCRIPTION; PRURITUS; RASH; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SORE THROAT; STOMACH DISCOMFORT; SYNCOPE; SYSTEMATIC REVIEW; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VOMITING;

CLINICAL TRIALS AS TOPIC; DRUG PRESCRIPTIONS; FATTY ACIDS, OMEGA-3; HUMANS; HYPERLIPIDEMIAS;

EID: 67651180722     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/SMJ.0b013e31819b08f7     Document Type: Review

References (46)

1. Rosamond W, Flegal K, Friday G, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007;115:e69-e171.
2. Yusuf S, Hawken S, Ounpuu S, et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952. (Pubitemid 39208455)
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
4. Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-239.
5. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
6. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-2828. (Pubitemid 17178359)
7. Barter P, Gotto AM, LaRosa JC, et al. Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310.
8. Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-2445.
9. Koro CE, Bowlin SJ, Stump TE, et al. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J 2006;151:755.e1-755.e6.
10. Bays HE. Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2004;2:485-501.
11. Abdel-Maksoud MF, Hokanson JE. The complex role of triglycerides in cardiovascular disease. Semin Vasc Med 2002;2:325-333.
12. Liu J, Sempos CT, Donahue RP, et al. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 2006;98:1363-1368. (Pubitemid 44666646)
13. Cui Y, Blumenthal RS, Flaws JA, et al. Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality. Arch Intern Med 2001;161:1413-1419. (Pubitemid 32681162)
14. Robinson JG, Wang S, Smith BJ, et al. Meta-Analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease. J Am Coll Cardiol 2009;53:316-322.
15. Davidson MH, Stein EA, Bays HE, et al. COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007;29:1354-1367.
16. Hokanson JE. Hypertriglyceridemia and risk of coronary heart disease. Curr Cardiol Rep 2002;4:488-493.
17. Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol 2006;1:389-420.
18. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007;49:1753-1762.
19. Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106-107.
20. Van Ganse E, Souchet T, Laforest L, et al. Ineffectiveness of lipid-lowering therapy in primary care. Br J Clin Pharmacol 2005;59:456-463. (Pubitemid 40523890)
21. Bays H. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol 2006;97:6C-26C.
22. Yokoyama M, Origasa H, Matsuzaki M, et al. Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-1098.
23. Steiner G. Lipid intervention trials in diabetes. Diabetes Care 2000;23:B49-B53.
24. Blankenhorn DH, Nessim SA, Johnson RL, et al. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-3240.
25. Cashin-Hemphill L, Mack WJ, Pogoda JM, et al. Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up. JAMA 1990;264:3013-3017.
26. Kane JP, Malloy MJ, Ports TA, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-3012.
27. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592. (Pubitemid 33126837)
28. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-418.
29. Bays H, Stein EA. Pharmacotherapy for dyslipidaemia - current therapies and future agents. Expert Opin Pharmacother 2003;4:1901-1938. (Pubitemid 37408104)
30. Harper CR, Jacobson TA. An evidence-based approach to the use of combination drug therapy for mixed dyslipidemia. JCOM 2006;13:57.
31. Merck/Schering-Plough Pharmaceuticals. Zetia® (ezetimibe) Tablets [Prescribing Information]. North Wales, PA, Merck/Schering-Plough Pharmaceuticals, 2008.
32. McKenney JM, Farnier M, Lo KW, et al. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006;47:1584-1587.
33. Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 2003;4:779-790.
34. Paolini JF, Mitchel YB, Reyes R, et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-630.
35. Bays H, Davidson MH, Stein EA, et al. Efficacy and safety of micronized fenofibrate-130 mg taken with or without food versus placebo in patients with hypertriglyceridemia and metabolic syndrome - TRIMS study (Triglyceride Reduction in Metabolic Syndrome) [abstract 750]. Endocr Pract 2005;11(Suppl 1):35.
36. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007;99:35C-43C.
37. GlaxoSmithKline. Lovaza® (Omega-3-Acid Ethyl Esters) Capsules [Prescribing Information]. Research Triangle Park, NC, GlaxoSmithKline, 2008.
38. Maki KC, McKenney JM, Reeves MS, et al. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia. Am J Cardiol 2008;102:429-433.
39. Maki KC, Lubin BC, Reeves MS, et al. Prescription omega-3 acid ethyl esters plus simvastation. J Clin Lipid 2009;33-38.
40. Harris WS, Bulchandani D. Why do omega-3 fatty acids lower serum triglycerides? Curr Opin Lipidol 2006;17:387-393. (Pubitemid 44079475)
41. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J Lipid Res 2003;44:455-463. (Pubitemid 37279692)
42. Harris WS, Miller M, Tighe AP, et al. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 2008;197:12-24.
43. Bays HE, Tighe AP, Sadovsky R, et al. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications. Expert Rev Cardiovasc Ther 2008;6:391-409.
44. Bays H. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Am J Cardiol 2006;98:71i-76i. (Pubitemid 44223366)
45. Oscient Pharmaceuticals. Antara® (fenofibrate) Capsules [Prescribing Information]. Waltham, MA, Oscient Pharmaceuticals, 2006.
46. Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol 2007;99:44C-46C.